SAB Biotherapeutics

COVID end of pandemic over jump leap virus coronavirus

A 'live fire exercise' with COVID preps SAB for new (old) focus

SAB signed a small contract with the DOD in September 2019 to develop an antibody for “an unknown threat.” Little did they know what they were in for.

Annalee Armstrong Oct 16, 2023 6:00am

field plow tractor wheat farm dust row plant grow

SAB's COVID-19 drug tries to find footing in omicron era

Apr 26, 2023 2:42pm

SAB vows to plow ahead with COVID-19 therapy after NIH drops out

Apr 1, 2022 10:35am

Synairgen ACTIV-2 trial paused while NIH tweaks study design

Mar 3, 2022 3:30pm

SAB Biotherapeutics banks $60M more for COVID-19 antibody

Sep 22, 2021 3:35pm